Trials / Completed
CompletedNCT06089824
Drug Utilisation of Mysimba/Contrave
Drug Utilisation and Safety Study of Mysimba in Europe and Contrave in the United States
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 43,324 (actual)
- Sponsor
- Currax Pharmaceuticals · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study will assess a retrospective cohort of users of Mysimba/Contrave with up to 548 days (\~18 months) after initiation with treatment with Mysimba/Contrave. This study will describe Mysimba/Contrave utilisation and incidence of AESIs for users compliant and non-compliant with the SmPC.
Conditions
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2022-10-01
- Completion
- 2022-10-01
- First posted
- 2023-10-18
- Last updated
- 2023-10-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06089824. Inclusion in this directory is not an endorsement.